Next Article in Journal
Understanding the Attitudes and Beliefs of Oncologists Regarding the Transitioning and Sharing of Survivorship Care
Previous Article in Journal
Extent of Groin Dissection in Melanoma: A Mixed-Methods, Population-Based Study of Practice Patterns and Outcomes
Review

Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus

1
Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada
2
Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC H2L 4M1, Canada
3
Department of Medicine, McMaster University, Hamilton, ON L8N 4A6, Canada
4
Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
5
Department of Hematology, Royal University Hospital, Saskatoon, SK S7N 0W8, Canada
6
Department of Medicine, QEII Health Sciences Centre, Dalhousie University, Halifax, NS B3H 3A7, Canada
7
Department of Medicine, University of Calgary, Foothills Hospital, Calgary, AB T2N 2T9, Canada
8
Department of Medicine, Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada
9
Department of Medicine, University of Alberta, Edmonton, AB T5J 2J7, Canada
10
Department of Medicine, University of British Columbia, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 5434-5451; https://doi.org/10.3390/curroncol28060453
Received: 17 September 2021 / Revised: 2 December 2021 / Accepted: 13 December 2021 / Published: 18 December 2021
Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous thromboembolism (VTE) and major bleeding complications. Risks vary significantly between individuals based on cancer status, treatment, and other characteristics. To facilitate the evidence-based management of anticoagulant therapy in this patient population, a committee of 11 Canadian clinical experts updated a consensus-based algorithm for the acute and extended treatment of symptomatic and incidental CAT that was developed in 2018. Following a systematic review of the literature, updates to the algorithm were discussed during an online teleconference, and the algorithm was subsequently refined based on feedback from committee members. Clinicians using this treatment algorithm should consider bleeding risk, type of cancer, and drug–drug interactions, as well as patient and clinician preferences, in tailoring anticoagulation for patients with CAT. Anticoagulant therapy should be adapted as the patient’s cancer status and management change over time. View Full-Text
Keywords: cancer-associated thrombosis; venous thromboembolism; pulmonary embolism; anticoagulation cancer-associated thrombosis; venous thromboembolism; pulmonary embolism; anticoagulation
Show Figures

Figure 1

MDPI and ACS Style

Carrier, M.; Blais, N.; Crowther, M.; Kavan, P.; Le Gal, G.; Moodley, O.; Shivakumar, S.; Suryanarayan, D.; Tagalakis, V.; Wu, C.; Lee, A.Y.Y. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Curr. Oncol. 2021, 28, 5434-5451. https://doi.org/10.3390/curroncol28060453

AMA Style

Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Suryanarayan D, Tagalakis V, Wu C, Lee AYY. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Current Oncology. 2021; 28(6):5434-5451. https://doi.org/10.3390/curroncol28060453

Chicago/Turabian Style

Carrier, Marc, Normand Blais, Mark Crowther, Petr Kavan, Grégoire Le Gal, Otto Moodley, Sudeep Shivakumar, Deepa Suryanarayan, Vicky Tagalakis, Cynthia Wu, and Agnes Y.Y. Lee. 2021. "Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus" Current Oncology 28, no. 6: 5434-5451. https://doi.org/10.3390/curroncol28060453

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop